Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZE9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,629
Award facts
- Contract value 100% obligated
- $17,628.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,628.86 to DMS Pharmaceutical Group Inc. on January 12, 2026, for the supply of Cabometyx 40 mg tablets (30-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is firm fixed-price and carries an ultimate completion date of January 13, 2026, with performance to be fulfilled at the vendor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That overarching contract, valued at $499,999,999 and awarded on November 13, 2025, positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy designed to support recurring pharmaceutical and medical supply needs across Department of Defense military healthcare facilities worldwide. The company's established track record supplying a diverse portfolio of branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals demonstrates its capability to fulfill the specialized requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCZE9?
SPE2DR26FCZE9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCZE9 worth?
The government has obligated $17,629 on SPE2DR26FCZE9.
Is contract SPE2DR26FCZE9 an order under another contract?
Yes. SPE2DR26FCZE9 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZE9 competed?
The extent of competition for SPE2DR26FCZE9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award